Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts

US-China biotech deals are expected to thrive because Washington is reportedly leaning away from sweeping restrictions, according to analysts, giving Chinese healthcare firms a major boost following Beijing’s ambitious five-year plan for…